ES2172514T3 - Tolerancia inducida a los xenoinjertos. - Google Patents

Tolerancia inducida a los xenoinjertos.

Info

Publication number
ES2172514T3
ES2172514T3 ES93903046T ES93903046T ES2172514T3 ES 2172514 T3 ES2172514 T3 ES 2172514T3 ES 93903046 T ES93903046 T ES 93903046T ES 93903046 T ES93903046 T ES 93903046T ES 2172514 T3 ES2172514 T3 ES 2172514T3
Authority
ES
Spain
Prior art keywords
xenoinjertos
induited
tolerance
mammer
receiving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93903046T
Other languages
English (en)
Inventor
David H Sachs
A Benedict Cosimi
Megan Sykes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of ES2172514T3 publication Critical patent/ES2172514T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE CARACTERIZA POR MEDICAMENTOS PENSADOS PARA PROLONGAR LA VIDA DE UN ORGANO IMPLANTADO (UN XENOINJERTO) DE UN MAMIFERO DONANTE QUE SOBREVIVE EN UN MAMIFERO RECEPTOR DE UNA ESPECIE DISCORDANTE ANTES DE RECHAZO. TAL MEDICAMENTO SE PREPARA MEZCLANDO CON UNA SUSTANCIA PORTADORA FARMACEUTICAMENTE ACEPTABLE CELULAS DE TALLO HEMATOPOIETICO, DEL MAMIFERO DONANTE PARA LA INTRODUCCION DENTRO DEL ANIMAL RECEPTOR.
ES93903046T 1992-01-08 1993-01-07 Tolerancia inducida a los xenoinjertos. Expired - Lifetime ES2172514T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81776192A 1992-01-08 1992-01-08
US83859592A 1992-02-19 1992-02-19

Publications (1)

Publication Number Publication Date
ES2172514T3 true ES2172514T3 (es) 2002-10-01

Family

ID=27124202

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93903046T Expired - Lifetime ES2172514T3 (es) 1992-01-08 1993-01-07 Tolerancia inducida a los xenoinjertos.

Country Status (11)

Country Link
US (1) US6296846B1 (es)
EP (1) EP0621786B1 (es)
JP (1) JPH07503012A (es)
AT (1) ATE215375T1 (es)
AU (3) AU679437B2 (es)
CA (1) CA2126094A1 (es)
DE (1) DE69331778T2 (es)
DK (1) DK0621786T3 (es)
ES (1) ES2172514T3 (es)
PT (1) PT621786E (es)
WO (1) WO1993013785A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010033840A1 (en) * 1994-04-25 2001-10-25 Trustees Of Dartmouth College Methods for inducing T cell tolerance to a tissue or organ graft
DE69723888T2 (de) 1996-05-09 2004-05-27 The General Hospital Corp., Boston Gemischter Chimerismus und Toleranz
EP0983074B1 (en) * 1997-05-23 2003-07-30 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
US6428782B1 (en) 1997-05-23 2002-08-06 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
US6447767B1 (en) 1997-05-23 2002-09-10 Hadasit Medical Research Services And Development Ltd. Non-myeloablative tolerogenic treatment
ATE439137T1 (de) 1997-11-14 2009-08-15 Gen Hospital Corp Behandlung von hämatologischen störungen
CA2319448A1 (en) 1998-02-04 1999-08-12 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allotransplantation
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
IL159270A0 (en) * 2001-06-14 2004-06-01 Yissum Res Dev Co Non-myeloablative tolerogenic treatment with tyrphostins
US7258839B2 (en) * 2001-12-21 2007-08-21 Cytonome, Inc. Temperature controlled microfabricated two-pin liquid sample dispensing system
WO2003060083A2 (en) * 2002-01-15 2003-07-24 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
KR20070073773A (ko) * 2004-09-10 2007-07-10 코그네이트 세러퓨틱 인크. 이식에서 면역반응의 예방 및 치료를 위한 간 기질세포
EP1859028B1 (en) 2005-02-10 2015-12-02 Regents Of The University Of Minnesota Vascular endothelial cells
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
EP3229586B1 (en) 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease
US11819520B2 (en) 2018-02-23 2023-11-21 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
AU2019225151B2 (en) 2018-02-23 2026-02-05 Duke University Cultured thymus tissue transplantation promotes donor-specific tolerance to allogeneic solid organ transplants
US12364715B2 (en) 2018-02-23 2025-07-22 Enzyvant Therapeutics Gmbh Methods of determining the suitability of cultured thymus tissue for implantation into humans and associated methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772552A (en) 1984-04-23 1988-09-20 Dana-Farber Cancer Institute, Inc. Monoclonal antibody which recognizes a 200-220 KD antigen on natural killer cells
US5160490A (en) * 1986-04-18 1992-11-03 Marrow-Tech Incorporated Three-dimensional cell and tissue culture apparatus
US5087570A (en) * 1988-05-10 1992-02-11 Weissman Irving L Homogeneous mammalian hematopoietic stem cell composition

Also Published As

Publication number Publication date
EP0621786A1 (en) 1994-11-02
ATE215375T1 (de) 2002-04-15
US6296846B1 (en) 2001-10-02
DK0621786T3 (da) 2002-04-29
CA2126094A1 (en) 1993-07-22
PT621786E (pt) 2002-07-31
JPH07503012A (ja) 1995-03-30
AU3989597A (en) 1998-01-08
WO1993013785A1 (en) 1993-07-22
EP0621786A4 (en) 1994-12-14
DE69331778D1 (de) 2002-05-08
AU679437B2 (en) 1997-07-03
AU759994B2 (en) 2003-05-01
EP0621786B1 (en) 2002-04-03
AU3440093A (en) 1993-08-03
DE69331778T2 (de) 2002-11-14
AU3017000A (en) 2000-06-29

Similar Documents

Publication Publication Date Title
FI864665A0 (fi) Lääkeaineille tarkoitettuja kantajakoostumuksia, jotka sisältävät hydroksipropyyliselluloosaeettereitä
ES2002089T3 (es) Nuevas formulaciones farmaceuticas con liberacion programada que contienen antiflogisticos.
ES2084174T3 (es) Productos y procesos para el tratamiento del conducto alimentario.
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
ES2010226A6 (es) Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos
NO873244D0 (no) Legemiddel.
NO953278L (no) Fremgangsmåter for in vivo-levering av biologisk aktive stoffer og sammensetninger som er nyttige for dette
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
ES2035086T3 (es) Procedimiento para preparar una composicion solida y estable que contiene ibuprofeno y codeina.
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.
UY25192A1 (es) Formulación medicamentosa con liberación controlada de sustancia activa
ES525574A0 (es) Procedimiento para producir preparaciones farmaceuticas que contienen como substancias activas derivados de polialquilenglicol.
DE69624937D1 (de) Verfahren zur verminderung der strahlentherapie oder der radiomimetischen chemotherapie bei der transplantation von hematopoietischen, pluripotenten zellen
DK0542860T3 (da) Immunosuppressive sammensætninger
ES2095861T3 (es) Composiciones con antibioticos estabilizadas para la alimentacion animal.
ATE6358T1 (de) 2-aminotetralin-verbindungen und pharmazeutische zusammensetzungen mit zentraler alpha1-agonist- wirksamkeit.
AP2000001821A0 (en) Formulations comprising dissolved paroxetine.
ES2039489T3 (es) La utilizacion del compuesto alquilidenditio-bis-(substituidos)-fenoles sustituidos.
ES2067906T3 (es) Composiciones farmaceuticas de somatostatina con resorcion mejorada, su preparacion y uso.
FR2427328A1 (fr) Ethers diphenyliques et medicament contenant ces substances
AR004165A1 (es) Una sal de diclavulanato de bis-(2-dialquilaminoalquil)-eter; un procedimiento para preparar la misma; y una composicion farmaceutica que la contiene
ES2040774T3 (es) Procedimiento para la preparacion de una formulacion medicamentosa.
ES2126923T3 (es) 8-fluoro-antraciclinas, procedimientos para su preparacion y composiciones farmaceuticas que las contienen.
ES2053683T3 (es) Forma de medicamento de aplicacion oral para el tratamiento de la hipertension una vez al dia con hidrocloruro de diltiazem.
ES2053561T3 (es) Metodos y composiciones para inhibir cataratas secundarias.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 621786

Country of ref document: ES